139 related articles for article (PubMed ID: 32562975)
1. BRAF and NRAS mutated melanoma: Different Ca
Esteves GNN; Ferraz LS; Alvarez MMP; Costa CAD; Lopes RM; Tersariol ILDS; Rodrigues T
Cell Calcium; 2020 Sep; 90():102241. PubMed ID: 32562975
[TBL] [Abstract][Full Text] [Related]
2. Suppressing Effect of Na
Liu Z; Cheng Q; Ma X; Song M
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055084
[TBL] [Abstract][Full Text] [Related]
3. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
[No Abstract] [Full Text] [Related]
4. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
[TBL] [Abstract][Full Text] [Related]
5. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
6. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
7. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
8. NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
Parekh V; Sobanko J; Miller CJ; Karakousis G; Xu W; Letrero R; Elenitsas R; Xu X; Elder DE; Amaravadi R; Schuchter LM; Nathanson KL; Wilson MA; Chu EY
J Cutan Pathol; 2019 Mar; 46(3):190-194. PubMed ID: 30552700
[TBL] [Abstract][Full Text] [Related]
9. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
10.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
11. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
12. The plasma membrane Ca
Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
[TBL] [Abstract][Full Text] [Related]
13. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
14. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
15. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
17. Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas.
Hirata AS; Rezende-Teixeira P; Machado-Neto JA; Jimenez PC; Clair JJ; Fenical W; Costa-Lotufo LV
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885944
[TBL] [Abstract][Full Text] [Related]
18. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
[No Abstract] [Full Text] [Related]
19. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
20. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
